FAQ: Quantumzyme's Removal of OTC Markets Caveat Emptor Designation

What does the removal of the ‘Caveat Emptor’ designation mean for Quantumzyme?

The removal signifies that Quantumzyme has met OTC Markets’ disclosure and compliance standards, now appearing as a Current Information issuer with a Verified Profile.

Why was the ‘Caveat Emptor’ designation removed?

It was removed following Quantumzyme’s full cooperation with OTC Markets, implementation of enhanced disclosure practices, and ensuring full regulatory compliance.

How did Quantumzyme achieve the removal of the ‘Caveat Emptor’ designation?

By updating financial reports, verifying identity, enhancing corporate transparency, and retaining experienced securities counsel to ensure compliance.

Who is affected by this change?

Investors and the investing public are affected, as the removal enhances the company’s market integrity and transparency.

When was the ‘Caveat Emptor’ designation removed?

The announcement was made on July 24, 2025, though the exact date of removal by OTC Markets is not specified.

What are the implications of this removal for Quantumzyme?

It allows Quantumzyme to focus on its business strategy and building shareholder value without the previous market warning.

How does Quantumzyme plan to maintain its compliance and transparency moving forward?

By committing to open communication, the highest standards of corporate governance, and continued cooperation with regulatory bodies.

Where can I find more information about Quantumzyme’s current status?

For the most current information, visit Quantumzyme’s website at www.quantumzymecorp.com or its OTC Markets profile at www.otcmarkets.com/stock/QTZM.

What was Quantumzyme’s stance on the unauthorized promotional messages circulated in March 2025?

Quantumzyme had no involvement in these messages, condemns such activity, and has cooperated fully with all related inquiries.